Products
Pre-Made Ramatercept Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting GDF8/MSLHP for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-967
Pre-Made Ramatercept Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting GDF8/MSLHP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ramatercept is a fusion protein of activin receptor type IIB and IgG1-Fc, which binds myostatin and related ligands. It aims to disrupt the inhibitory effect on muscle development and provide potential therapy for myopathies like Duchenne muscular dystrophy (DMD).
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-967-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-967-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-967-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-967-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Ramatercept Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting GDF8/MSLHP |
| INN Name | Ramatercept |
| Target | MSTN/GDF-8 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Acceleron Pharma, Inc (Cambridge UK) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
